The problem with what most doctors "know" about progesterone is that most of them are confused by the difference between real human progesterone (ie,P4, prometrium) and medroxyprogesterone acetate (provera/MPA) which is a progestin with remarkably different side effect profiles. The biggest differences in adding P4 is cardiovascular, mental and libido.
Some light reading if you are interested.
http://www.ncbi.nlm.nih.gov/pubmed/15358673http://www.ncbi.nlm.nih.gov/pubmed/22834417HRT and Your Genes: Breast Cancer RIsk or Not?
---Depends on whether your HRT is Bio-identical (estradiol and micronized Progesterone) or Toxic Synthetic ((Premarin and Medroxyprogesterone)
These results suggest that HRT with natural estrogens affects a much smaller number of genes and has less-adverse effects on the normal breast in vivo than conventional, synthetic therapy.
The synthetic therapy significantly enhanced mammographic breast density, an important risk factor for breast cancer.
Two 28-day cycles of daily estradiol (E2) gel 1.5 mg and oral micronized progesterone (P) 200 mg/day for the last 14 days of each cycle did not significantly increase breast epithelial proliferation at the cell level nor at the mRNA level ).
By contrast, two 28-day cycles of daily oral conjugated equine estrogens (CEE) 0.625 mg and oral medroxyprogesterone acetate (MPA) 5 mg for the last 14 days of each cycle significantly increased proliferation at both the cell level and at the mRNA level, and significantly enhanced mammographic breast density, an important risk factor for breast cancer.
In addition, CEE/MPA affected around 2,500 genes compared with just 600 affected by E2/P.
http://www.ncbi.nlm.nih.gov/pubmed/?term=Novel+Perspectives+for+Progesterone+in+Hormone+Replacement+Therapy%2C+with+Special+Reference+to+the+NervousNovel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system.
Schumacher M1, Guennoun R, Ghoumari A, Massaad C, Robert F, El-Etr M, Akwa Y, Rajkowski K, Baulieu EE.
Author information
Abstract
The utility and safety of postmenopausal hormone replacement therapy has recently been put into question by large clinical trials. Their outcome has been extensively commented upon, but discussions have mainly been limited to the effects of estrogens. In fact, progestagens are generally only considered with respect to their usefulness in preventing estrogen stimulation of uterine hyperplasia and malignancy. In addition, various risks have been attributed to progestagens and their omission from hormone replacement therapy has been considered, but this may underestimate their potential benefits and therapeutic promises. A major reason for the controversial reputation of progestagens is that they are generally considered as a single class. Moreover, the term progesterone is often used as a generic one for the different types of both natural and synthetic progestagens. This is not appropriate because natural progesterone has properties very distinct from the synthetic progestins. Within the nervous system, the neuroprotective and promyelinating effects of progesterone are promising, not only for preventing but also for reversing age-dependent changes and dysfunctions. There is indeed strong evidence that the aging nervous system remains at least to some extent sensitive to these beneficial effects of progesterone. The actions of progesterone in peripheral target tissues including breast, blood vessels, and bones are less well understood, but there is evidence for the beneficial effects of progesterone. The variety of signaling mechanisms of progesterone offers exciting possibilities for the development of more selective, efficient, and safe progestagens. The recognition that progesterone is synthesized by neurons and glial cells requires a reevaluation of hormonal aging.
http://www.cpementalhealth.com/content/4/1/3